TIOMAX: A Spanish Multicenter Registry of the real-world use of the TItanium OptiMAX® biostent: TIOMAX: Registro Español Multicéntrico Del Biostent De Titanio OptiMAX® En La Vida Real
| Autor: | Juan Manuel Nogales-Asensio, Joan Antoni Gómez-Hospital, Juan Francisco Oteo-Domínguez, Victor M Aragón-Extremera, Jesús M. Jiménez-Mazuecos, Fernando Carrasco, Francisco Bosa-Ojeda, José R. López-Mínguez, Fernando Rivero-Crespo, Sebastián Romaní |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
business.industry medicine.medical_treatment Mortality rate Percutaneous coronary intervention Stent General Medicine 030204 cardiovascular system & hematology Revascularization medicine.disease Surgery 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Clinical endpoint Radiology Nuclear Medicine and imaging 030212 general & internal medicine Stent thrombosis Myocardial infarction Cardiology and Cardiovascular Medicine business Target lesion revascularization |
| Zdroj: | Catheterization and Cardiovascular Interventions. 92:261-268 |
| ISSN: | 1522-1946 |
| Popis: | Objectives To compare the safety and efficacy of the new cobalt-chromium bioactive stent Titan Optimax® (Hexacath, France) with its predecessor, Titan-2®. Background The TIOMAX registry includes 784 patients who underwent percutaneous coronary intervention with these stents in 21 Spanish hospitals. Methods Analysis of all patients in the registry without exclusion criteria, candidates for revascularization (March-2013/July-2014). Initially 273 patients received Titan-2®, and the next 511 received the Optimax® after its launch. Results Mean age was 65.8 ± 13.0 (78.1% men); 49.2% were STEACS patients (n = 322), 29.8% NSTEACS, and 27.3% had stable angina or silent ischemia. Most STEACS patients (76.4% of n = 322) were treated |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text